Scleroderma Newsroom
ISN News Manager: Jo Frowde
Media Stories
Scleroderma Archive
We maintain news archives for the most recent 3 years.
2018: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2021 - 2020 - 2019 - 2018

April 2018 Scleroderma News

The safety of iloprost (ILO) in systemic sclerosis in a real–life experience. Our data suggest that calcium channel blockers should be transitorily stopped while using ILO and that a pre–treatment approach might reduce or control adverse events. PubMed, Clin Rheumatol, 02/22/2018. (Also see Inhaled Prostacyclin (Iloprost, Ventavist))

The impact of malnutrition on quality of life in patients with systemic sclerosis. Standardized nutritional screening should routinely be conducted to identify the risk of malnutrition in order to enable an intervention with multimodal treatment. PubMed, Eur J Clin Nutr, 03/08/2018. (Also see Diet and Systemic Scleroderma and QOL with Scleroderma)

Evaluation and management of esophageal manifestations in systemic sclerosis (SSc). This review summarizes our knowledge concerning the evaluation and management of esophageal manifestations in SSc patients, including emerging therapeutic modalities. Pubmed, Ann Gastroenterol, 2018 Mar-Apr;31(2):165-170. (Also see Gastrointestinal Involvement)

Case Report: Imaging Helps Guide Physical Therapy Treatment in a Patient With Diffuse Systemic Sclerosis (Scleroderma). Because finger joint spaces appeared normal, joint mobilization, which would have been contraindicated by bone or joint destruction, was considered appropriate to help increase range of motion. PubMed, J Orthop Sports Phys Ther, 2018 Mar;48(3):226. (Also see Hand and Joint Involvement)

Angiogenic and inflammatory biomarkers for screening and follow-up in patients with pulmonary arterial hypertension (PAH). Plasma levels of PlGF, sVEGFR-1, TNF-a, and VEGF-D have potential in screening for SSc–associated PAH. Plasma sVEGFR-1 may be a biomarker of treatment response. PubMed, Scand J Rheumatol, 2018 Mar 12:1-6. (Also see Pulmonary Hypertension Diagnosis)

Ultrasound (US) characterization of cutaneous ulcers in systemic sclerosis (SSc). US may support the assessment of morphology and extent of skin ulcers in SSc and can be a helpful tool for detecting underlying pathology. PubMed, Clin Rheumatol, 03/10/2018. (Also see Digital Ulcers)

Evaluation of Changes in Corneal Biomechanics in Patients with Systemic Sclerosis. In the course of the disease SSc leads to various alterations in connective tissue, which can also involve corneal tissue. PubMed, Klin Monbl Augenheilkd, 03/07/2018. (Also see Eye Involvement)

iBio Selects Lead Candidate for its Fibrosis Therapeutics Program. iBio, Inc. announced today that it had selected an E4-Fc fusion protein as its lead candidate for further development of a drug against fibrotic diseases, including systemic sclerosis and idiopathic pulmonary fibrosis. Globe Newswire, 03/14/2018. (Also see Scleroderma Clinical Trials)

Inflammatory arthritis in pediatric patients with morphea. Pediatric morphea co–existed with inflammatory arthritis in 11 out of 53 children and further understanding and appreciation of this relationship may direct more intensive therapy and musculoskeletal screening. PubMed, J Am Acad Dermatol, 03/10/2018. (Also see Morphea)

Nintedanib Gets Fast Track Designation for Treatment of Systemic Sclerosis. Boeringer Ingelheim announced this morning that the U.S. Food and Drug Administration (FDA) granted Fast Track designation to nintedanib for the treatment of systemic sclerosis with associated interstitial lung disease (SSc-ILD). Rare Disease Report, 03/19/2018. (Also see Scleroderma Clinical Trials)

Go to Scleroderma Medical News: March 2018

SCLERO.ORG is the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses. We are a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team. Donations may also be mailed to:

International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA
Email [email protected]. Disclaimer. Privacy Policy.